Xingqi Eye Medicine: Obtained the drug registration certificate for Bromonidine Tartrate Eye Drops

MetaMuskRat · 2026-04-04T18:08:48+00:00

People's Financial News, April 3 — Xingqi Eye Medicine (300573) announced on April 3 that today, the company received the "Drug Registration Certificate" for Brimonidine Tartrate Eye Drops approved and issued by the National Medical Products Administration. The approved Brimonidine Tartrate Eye Drops are a multi-dose formulation, indicated for lowering intraocular pressure in patients with open-angle glaucoma and ocular hypertension. As of now, generic versions of the same product have been approved and launched domestically.

MetaMuskRat

2026-04-04 18:08:48

People’s Finance & News April 3, Xingqi Eye Hospital (300573) announced on April 3 that today, the company received the Balsamine acetate bromide monostatine ophthalmic solution “Drug Registration Certificate” approved and issued by the National Medical Products Administration. The approved Balsamine acetate bromide monostatine ophthalmic solution is a multi-dose product. The indication is for lowering intraocular pressure in patients with open-angle glaucoma and ocular hypertension. As of now, a generic drug of the same product has been approved for marketing in China.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.